Subsidiary obtains South Korean drug import license
August 2, 2025
Source: drugdu
112
Jincheng Pharmaceutical(300233.SZ) announced that its wholly-owned subsidiary, Beijing Jincheng Taier Pharmaceutical Co., Ltd., recently received a drug import license for Promestriene Cream from the Korean Ministry of Food and Drug Safety. This product, a strictly localized estrogen, is indicated for atrophic lesions of the vulva, vestibule, and vaginal ring, as well as the subjective symptoms associated with them. Promestriene Cream's receipt of drug import approval from the Korean MFDS signifies that the product has secured market access in South Korea, positively impacting the company's expansion into the Korean pharmaceutical market and boosting sales in overseas markets.
Source：https://finance.eastmoney.com/a/202507313472756619.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
